Seattle Genetics wins priority review for Hodgkin's/ALCL drug, but US FDA splits app
02 May 2011
Donna Young
Please Login to read the full article.
02 May 2011
Donna Young
donna.young@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA's Pazdur urges Seattle Genetics to connect quickly with agency post-positive ODAC
- Nearly smooth sailing predicted at ODAC for Seattle Genetics' lymphoma drug
- EMA accepts Takeda/Millennium's Adcetris for review
- Early Adcetris OK no surprise to SGEN after taking US FDA's advice
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
